12 unknown, 9 completed, 8 recruiting, 1 active not recruiting. 6 Not applicable, 4 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 2, Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 4 | Recruiting 3, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
Follow Progression: new trials by email Literature Review of Progression trials Research Report on Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Construction of a Cohort of Elderly Patients With Atrial Fibrillation in Rural China Atrial Fibrillation (AF), Heart Failure | Recruiting | Jiangsu Taizhou People's Hospital | 2500 | 2026-03-14 | 2026-05-28 | |
| Omitting CTV for Primary Tumor in LS-SCLC Radiation Therapy, Etoposide + carboplatin; Etoposide + cisplatin, Creating CTV for primary tumor - SCLC, Limited Stage, Radiation Exposure | Phase 3 | Recruiting | Sun Yat-sen University | 852 | 2025-06-03 | 2025-06-06 |
| The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) the labour care guide (LCG) - Labor Dystocia, Labor Complication | Not applicable | Recruiting | Ostfold Hospital Trust | 23650 | 2025-04-01 | 2025-04-04 |
| Effects of Progressive Relaxation Exercises Progressive Relaxation Exercise - Nursing Caries, Progression | Not applicable | Completed | Kutahya Health Sciences University | 80 | 2025-01-25 | 2025-08-29 |
| The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination IHC: Immunohistochemistry, RNA-seq - Sarcoma, Biomarkers | Active not recruiting | Peking University People's Hospital | 200 | 2025-01-01 | 2025-07-10 | |
| Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer Analysis of diagnostic biomarkers - Lung Neoplasms, Progression | Unknown | Casa Sollievo della Sofferenza IRCCS | 20 | 2024-07-01 | 2024-06-18 | |
| Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors Everolimus 5 MG - Neuroendocrine Tumors, Progression | Phase 2 | Recruiting | AC Camargo Cancer Center | 100 | 2024-04-24 | 2024-06-25 |
| Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy - Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Yale University | 30 | 2023-12-22 | 2025-12-04 |
| Soluble B7-H3 as a Biomarker for Osteosarcoma ELISA: enzyme-linked immunosorbent assay - Biomarker, Progression | Unknown | Peking University People's Hospital | 200 | 2023-06-05 | 2024-05-14 | |
| Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial colchicine, Placebo - Colchicine, Abdominal Aortic Aneurysm | Not applicable | Unknown | Guangdong Provincial People's Hospital | 230 | 2022-06-01 | 2022-05-05 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
| A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1 selective lymph node dissection, Systemic Lymph Node Dissection - Progression, Postoperative Recovery | Not applicable | Not yet recruiting | Shanghai Zhongshan Hospital | 500 | 2022-01-01 | 2022-01-11 |
| Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation PreserFlo Microshunt - Glaucoma, Progression | Unknown | Klinikum Klagenfurt am Wörthersee | 100 | 2021-10-12 | 2023-12-18 | |
| Intrapartum Translabial Ultrasonography Reliability Transperineal ultrasound - Labour;Obstructed, Progression | Unknown | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | 80 | 2021-02-20 | 2023-03-21 | |
| A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules Ablation therapy - Progression | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 120 | 2021-01-01 | 2021-05-27 |
| A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components Lymphadenectomy - Progression | Not applicable | Recruiting | Shanghai Zhongshan Hospital | 1500 | 2020-09-01 | 2020-10-09 |
| Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression HCQ - Covid19, Progression | Phase 3 | Completed | UNICEF | 540 | 2020-04-10 | 2020-08-21 |
| Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer Blood serum: sUPAR, PAI-1, IL-8., Urine: IL-8, APOE, VEGF. - Non-muscle Invasive Bladder Cancer, Cystoscopy | Completed | Wroclaw Medical University | 240 | 2020-01-01 | 2024-02-01 | |
| Liver Disease and Other Systemic Diseases Liver Diseases, Humans | Recruiting | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 15000 | 2020-01-01 | 2025-09-19 | |
| Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma. prognosis - Renal Cell Carcinoma, Progression | Unknown | Corporacion Parc Tauli | 4666 | 2019-12-31 | 2020-01-02 |
Showing 20 of 33. Sign in to see all of them.
Disease Progression (33) · Neoplasms (3) · Recurrence (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Dystocia (2) · Liver Diseases (2) · Non-Muscle Invasive Bladder Neoplasms (2) · Osteosarcoma (2) · Urinary Bladder Neoplasms (2) · Adenoma, Islet Cell (1) · Aortic Aneurysm, Abdominal (1) · Atrial Fibrillation (1) · Brain Neoplasms (1) · COVID-19 (1)
Disease Attributes (33) · Pathologic Processes (33) · Pathological Conditions, Signs and Symptoms (33) · Neoplasms (13) · Neoplasms by Histologic Type (11) · Neoplasms by Site (10) · Female Urogenital Diseases and Pregnancy Complications (7) · Neoplasms, Glandular and Epithelial (7) · Urogenital Diseases (7) · Carcinoma (6) · Female Urogenital Diseases (5) · Male Urogenital Diseases (5) · Urologic Diseases (5) · Adenocarcinoma (4) · Cardiovascular Diseases (4)
Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Colchicine (1) · Etoposide (1) · Everolimus (1) · Hydroxychloroquine (1) · Ifosfamide (1) · Lymph Node Excision (1) · Phacoemulsification (1) · RNA-Seq (1) · Radiosurgery (1) · Radiotherapy (1) · Standard of Care (1) · Temozolomide (1)
Peking University People's Hospital (4) · Shanghai Zhongshan Hospital (3) · AC Camargo Cancer Center (1) · Biomea Fusion Inc. (1) · Casa Sollievo della Sofferenza IRCCS (1) · Copenhagen University Hospital, Hvidovre (1) · Corporacion Parc Tauli (1) · European Georges Pompidou Hospital (1) · Guangdong Provincial People's Hospital (1) · Hunan Province Tumor Hospital (1) · Jiangsu Taizhou People's Hospital (1) · Klinikum Klagenfurt am Wörthersee (1) · Kutahya Health Sciences University (1) · Kyorin University (1) · Mansoura University (1)
China (11) · United States (3) · Spain (2) · Turkey (Türkiye) (2) · Austria (1) · Brazil (1) · Denmark (1) · Egypt (1) · France (1) · Greece (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Pakistan (1)
Ahmed Mosbah, MD (1) · Angus Jones, MBBS MRCP (1) · Ching-Sheng Hsu, Ph.D (1) · Francoise Lepimpec Barthes, MD PhD (1) · Jianfang Luo, MD (1) · Jiang Wei (1) · Kimberly Johung, MD (1) · Klaudia Bardowska, MD (1) · Motoo Nagane, M.D., Ph.D. (1) · Murat Yassa, MD (1) · Nicholas Thomas, MRCP (1)
PMID 22252861, PMID 25027686, PMID 26508025, PMID 27274272, PMID 29726782, PMID 32077450, PMID 32598949, PMID 33288401, PMID 33546029, PMID 37189151, PMID 37973887, PMID 39928162